Clinical Trial Detail

NCT ID NCT03078751
Title Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)
Recruitment Active, not recruiting
Gender
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Age Groups: adult senior

Additional content available in CKB BOOST